Broad, multidimensional business background with expertise in healthcare inclusive of diagnostics, devices and life sciences. During a thirty year tenure in the healthcare industry, have held executive level positions in general management, sales, marketing, business development and international commercial operations. Consciously developed broad expertise across multiple disciplines and geographies, managing commercialization strategies and business operations on a global scale for companies such as Abbott, Digene and Beckman Coulter. Understand the workings of organizations from small start-ups to large, complex corporations. Excel at turning around under-performing operations and leading start-up businesses, global and regional commercialization strategies and product development in regulated markets.

Barry is responsible for overall foundry technology strategy and direction. He holds a PhD in Biological Engineering from MIT, where his thesis focused on refinement of standard biological parts and the interactions between a host cell and an engineered genetic circuit. At MIT, he was involved with the Synthetic Biology Working Group that was instrumental in catalyzing the new field. He also holds an MEngSc in Mechanical Engineering from University College Dublin.

Biotech executive and board director with extensive experience in leadership, business and corporate development, company setup & building, fundraising, investment, operation, R&D, manufacturing, marketing, and commercialization. Results-driven and passionate about partnerships to develop innovative technologies and products to make a difference in human health. Proven success in partnership, commercialization, and R&D. Experience in technologies, rare diseases, oncology, infectious disease, immunology, vaccines, genetic disorders, cardiovascular, cell & gene therapy, and personalized medicine.

Peter Clark, PhD is the Head of Computational Drug Design at Novo Nordisk, where he heads a global team of computational scientists focused on applying state-of-the-art computational approaches, platforms & tools to accelerate the discovery and development of differentiated therapeutics in order to sustain the portfolio pipeline across all therapeutic modalities through in silico molecular design and optimization. Prior to joining Novo Nordisk, Peter served as the Global Head of Computational Science & Engineering within the Therapeutics Discovery (TD) organization of Johnson & Johnson Innovative Medicines, where he led a team of wet and dry lab scientists working to develop novel drug discovery platforms and capabilities across the pharmaceutical value chain; supporting the advancement of several NMEs per year across therapeutic modalities. Prior to joining Johnson & Johnson, Peter served as the Director of Bioinformatics at the University of Pennsylvania, Perelman School of Medicine, where he worked closely with academic and commercial collaborators on the design, optimization, and evaluation of various gene therapy assets from early research and development through commercially partnered IND enabling clinical studies. Peter is also trained in clinical molecular genetics (The Children’s Hospital of Philadelphia), earned his B.Sc. and Ph.D. from Drexel University, School of Biomedical Engineering and has completed a postdoctoral fellowship at The Center for Computational Medicine at Thomas Jefferson University. Peter’s diverse expertise in computer science, engineering, clinical molecular genetics, computational biology, and translational research has led to the publication of over 60 peer-reviewed scientific publications as well as three book chapters, several issued patents and three biotechnology spin-off companies.

Biotech Venture Capital | Captain, United States Air Force (Veteran)

Lucy Colwell is a researcher on the Science team at Google DeepMind and a faculty member in chemistry at the University of Cambridge. Her primary interests are in the application of machine learning approaches to better understand the relationship between the sequence and function of biological macromolecules. Before moving to Cambridge Lucy received her PhD from Harvard University and held an EPSRC fellowship at the MRC-LMB and the Institute for Advanced Study in Princeton, NJ.

Brett rejoined F-Prime Capital in 2018 and focuses on investments in healthcare technology and service companies. Previously, he led finance, partnerships, and business operations at PatientPing, a healthcare technology company providing real-time admission and discharge notifications to coordinate patient care. Previously, Brett worked at Aledade, F-Prime Capital, and McKinsey & Company. Brett holds an M.B.A. from Harvard Business School and a B.S.E. in Biomedical Engineering from Duke University.

Cris joined Sanofi Ventures in 2020 to lead investments in AI and Digital Health. He holds a 20-year track record of building startups, tech innovation platforms, and healthtech deal-making with some of the largest organizations in the world. Prior to Sanofi, Cris was a founding member of Johnson & Johnson Innovation and Global Head of Digital Innovation since 2013. He held chief digital and data responsibilities, driving digital health strategy and new venture partnerships throughout spanning the Pharmaceutical, Consumer and Medical Device businesses.? Previously, Cris led emerging technology programs within research informatics at Novartis for six years. With entrepreneurial DNA, Cris is notably known for his role in the innovation economy since co-founding Ultra Light Startups, one of the largest and oldest startup venture pitch accelerators in the U.S, catalyzing hundreds of companies in Boston, NYC, and Silicon Valley, leading to several acquisitions by major tech companies. Cris was named 40 Under 40 by the Boston Business Journal and a Top 40 Healthcare Transformer by MM&M Magazine.? Cris currently serves on the boards of Aetion, Carbon Health, Click Tx, Empatica, Medisafe, Nucleai, and Omada. Cris holds a M.Sc. in Computer Information Systems from Boston University and a B.S. in Business Administration from Suffolk University.?

A former neuroscience researcher, Andrea’s portfolio career has included leadership assignments at the intersection of science, technology and business development. She has built and led informatics and scientific teams across the entire pharmaceutical value chain. Most recently, Andrea focused on building the Pharma Artificial Intelligence market at NVIDIA. Through this experience she has travelled the world advising biopharmaceutical, academics, research institutes, and startups in the potential of machine learning and artificial intelligence across every discipline in our industry. Prior to her role at NVIDIA, Andrea held leadership positions at the Broad Institute of Harvard and MIT, Amgen, and Roche. In the last three years, Andrea’s work at Eli Lilly & Company has focused around empowering the LRL Research organization with greater computational, analytics-intense experimentation to raise the innovation of our scientists. As the Global Head of Data Sciences and Advanced Analytics, Andrea leads four organizations: The High-Performance Computing Team, the Data Engineering team, the AI/ML team and the Translational Informatics team for LRL. Additionally, Andrea serves as a strategic advisor for the NIH HubMap Advisory Team. She has a B.S. in Animal Physiology from UC Davis, a Master’s in Health Administration from University of San Francisco, and an MBA from MIT Sloan. Her leadership has gained her international recognition as a leader in Big Data, Artificial Intelligence and Data Sciences.

Jessica Federer is a recognized leader in the global life sciences industry. She was the first Chief Digital Officer for the Bayer AG group, as well as the first woman to hold that role in the industry. She led Bayer’s digital transformation across the pharmaceutical, consumer care, crop science, material science and animal health businesses during record setting years for both sales and EBITDA. Reporting into the Bayer AG Group Management Board, Federer united the company’s digital strategy and investments across divisions to accelerate growth across the 118,00 employees. During her tenure, the company acquired and integrated Merck’s consumer care business and Monsanto, becoming, respectively, the second largest consumer health and the leading agriculture businesses on the planet, and floated their material science division into Covestro. With a focus on scalable digital enablers to business integrations and success, Federer streamlined investments, modernized capabilities, and upskilled the workforce. Prior to leading digital for the group business, Federer established a track record inside Bayer for delivery across regulatory affairs, market access, product launches, and business turnarounds. This includes the launch team for the record holding biologic EYLEA ®, an overhaul in the animal health business, and establishing the market access function globally. Federer regularly contributes to publications and events for the FT, Reuters Health, Bloomberg, and leading consultancies. Ms. Federer joined BMP as a Venture Affiliate in 2018, and is a Partner for the Opportunity Fund. She is a graduate of George Washington University and received an MPH from the Yale School of Public Health.

In his role at Google Cloud; Bill oversees a strategy and organization whose goal is to bring accelerated cloud-based scientific solutions to the fast-growing and ever-evolving Biotechnology segment. The Google Cloud Biotech organization aims to provide value from the top venture firms investing in early-stage biotechnology doing pre-clinical research through the numerous commercial opportunities; IPO, licensing partnerships, and commercialization. In support of the biotech ecosystem the organization partners with industry leaders, technology, and solution providers to assure that Google Cloud can deliver the best environment for the rapid evolution of science and return for its investors. The biotech solution organization and its partners deliver a number of solutions which lower the cost of scientific research across numerous modalities by utilizing Artificial Intelligence, Big Data, Gene Editing, Precision Medicine, Gene Sequencing as well as Synthetic Biology. Bill has over 15 years of experience in the biotech and biopharma ecosystem where he has led similar organizations at various startups and at EMC & Dell Technologies. He is a former founder of the Life Sciences User Groups in Cambridge, MA and a current member of the Massachusetts Biotech Council. He has a degree in Management Information Systems and executive certifications from Babson College.

Molly is an Origination Partner at Flagship Pioneering, working as part of a venture-creation team to found and grow companies at the intersection of biology and machine learning. Molly serves as co-founder & chief strategy and chief innovation officer of Generate:Biomedicines, a Flagship Pioneering company, where she has served many roles from R&D to corporate strategy, platform and data strategy, and launching an innovation group, called G:Labs that explores novel applications of The Generate Platform. Through her role in Flagship Labs, Molly has contributed to the launch and growth of Tessera Therapeutics and Cobalt Biomedicines, which was merged into Sana Biotechnology. Molly’s work has resulted in multiple pending patents and publications, including articles in Science and Nature. Molly was honored in 2020 in Endpoints News' 20 under 40 list in biopharma and in 2021 in Business Insiders’ list of 12 young serial entrepreneurs building the next generation of biotech startups. Molly received a PhD in computational and systems biology from Washington University in Saint Louis in the Center for Genome Sciences, with the support of a National Science Foundation Graduate Research Fellowship. At Washington University, Molly collaborated with St. Louis Children's Hospital to study the effects of early-life interventions on development of the preterm infant gut microbiome and health outcomes.

Mr. Goldberg is an Operating Partner of Arsenal where he focuses on networking and sourcing transactions for the healthcare team. Prior to joining Arsenal in 2014, Mr. Goldberg was a Managing Director, Corporate Development of Endo Pharmaceuticals. Previously, he was a founding Partner of ProQuest Investments and the founding CEO or founder of three biotechnology companies that were acquired or taken public. In addition, he also held executive positions at Becton Dickinson and at GSK. He serves on Dana Farber Cancer Institute Visiting Committee and board of NIH/Cambridge/Oxford Scholars program.

Robert C. Green, MD, MPH is a physician-scientist and Professor of Medicine at Harvard Medical School who directs the Genomes2People Research Program at Mass General Brigham, Ariadne Labs and the Broad Institute. Dr. Green’s empirical research has established the safety and feasibility of disclosing unanticipated genetic risk information in research studies and in population screening. He led the first federally funded clinical trials of genomic sequencing in healthy adults (the MedSeq Project) and in the active duty military personnel (the MilSeq Project), and currently leads the world’s first trial of sequencing in healthy newborn infants (the BabySeq Project). Dr. Green co-led the American College of Medical Genetics and Genomics working group that created the first recommendations for return of incidental genomic findings, establishing the “ACMG list” of actionable genes that has subsequently been used in many return-of-results protocols. Dr. Green leads the first grant to return genomic results in the Framingham Heart Study and the Jackson Heart Study, and has led policy development for returning genomic information to research participants within the Global Alliance for Genomics and Health, the Verily-Google Baseline Project and All of Us Research Program. He has also co-founded the telegenetics company Genome Medical and the newborn and childhood genomic screening company Nurture Genomics.

Luba Greenwood is a distinguished executive, investor, and company builder with over 20 years of experience in the healthcare and tech sectors. Luba has served as the Chief Executive Officer and Chair of the Board of Kojin Therapeutics, a leader in ferroptosis. She was previously the Managing Partner of the Dana Farber Cancer Institute Venture Fund, Binney Street Capital (BSC), which she has founded, investing and building companies across therapeutics, diagnostics, and digital sectors. She has also served as a lecturer at Harvard University in the School of Engineering and Applied Sciences. Ms. Greenwood has extensive board experience globally and serves on public and private boards, across multiple industries, including healthcare and tech, and has successfully contributed to the growth and profitability of numerous organizations, bringing her operational, industry, and financing expertise. She has a proven track record of building world-class teams and companies, building SABs with renown scientists and industry leaders, driving digital transformation and artificial intelligence initiatives, guiding companies through mergers & acquisitions, complex business development transactions, financing, and organizational change and scaling. With a strong understanding of board dynamics and corporate governance best practices, and as a former lawyer, she has also guided organizations through compliance, activist actions, and human resources challenges. She has served as Chair of the board as well as on the Compensation, Audit, and Nomination committees of a number of companies including In8Bio (INAB), BenchSci, Swiss-based Stalicla, Abcam (Abcam), where she has spearheaded the sale to Danaher (DHR), and non-profit, Massachusetts Biotechnology Council (MassBio). Ms. Greenwood has previously served in leadership roles at Google Life Sciences (Verily) and as Vice President of Global Business Development and Mergers & Acquisitions at Roche, where she also led diagnostics BD and established and led the East Coast Innovation Hub. Luba has led $5B+ in M&A, BD deals, and investments across multiple therapeutic areas, diagnostics, life sciences, and tech sectors globally. She has also co-founded and advised biotech and digital health companies in the immunotherapy, AI/ML, women's health, and microbiome space, including Luca Biologics. Her invaluable contributions to the healthcare industry have earned her recognition as a thought leader and a trusted advisor to CEOs of leading academic centers worldwide, including the Dana Farber Institute and Wyss Center for Bio and Neuroengineering in Geneva. She is a Thought Leader for the New England Journal of Medicine (NEJM) Catalyst and serves on Investor Committee for the National Cancer Institute. With a background as a former lawyer at Wilmer Cutler Pickering Hale and Dorr and expertise in regulatory, policy, and intellectual property matters, Ms. Greenwood brings a unique perspective to the table. Her commitment to advocating for women in science and technology has garnered several awards and honors, including the Science Club for Girls Catalyst Award.

Andrew Hedin is a partner in Bessemer’s Cambridge office where he focuses on investments broadly across the healthcare ecosystem, including new biotech therapeutics as well as software and services sold to healthcare verticals. Prior to joining Bessemer in 2015, Andrew worked at F-Prime Capital, Fidelity’s healthcare-focused venture capital fund where he invested in early-stage biotech and digital health technologies, as well as Leerink Partners as an advisor to the biopharma industry. He earned an MBA with honors from The Wharton School, where he majored in health care management and finance, as well as a degree in biological basis of behavior from the University of Pennsylvania.

As a venture partner at Third Rock, John works with the platform team to develop, implement, and refine technology roadmaps for companies across our portfolio with a focus on the identification and integration of drug discovery and development technology platforms. Prior to joining Third Rock, John was the vice president of information technology and informatics at Infinity Pharmaceuticals where he was responsible for information systems, software development, computational science, biostatistics, clinical data management, and clinical informatics. Over the course of almost 13 years at Infinity, John had the unique opportunity to play a critical role in the genesis and evolution of the company's science, technology, and business. John, who has proven to be a sucker for worthy charities, once allowed his coworker to shave his head with a Flowbee to raise money for a local nonprofit organization focused on cancer patient support.

Rory Kelleher is the global business development lead for healthcare and life sciences at NVIDIA. Rory is responsible for NVIDIA's industry go to market in biopharma, payer/provider, and healthcare research with the singular mission to bring state of the art AI and computing approaches to the world of Healthcare. Rory joined NVIDIA in 2016, shortly after the "Big Bang" of the machine learning revolution and spent several years helping organizations to build their initial AI strategies. Prior to NVIDIA, Rory spent a decade in various sales leadership roles at large technology firms Cisco and EMC. Outside of work, Rory enjoys exercise, the outdoors, and is passionate about individual mentorship as an active volunteer at Big Brother Big Sister of Eastern, MA.

Jae Won Kim is an accomplished C-level executive currently serving as the CFO-COO at VantAI, a biotechnology company leveraging artificial intelligence for drug discovery. With over 15 years of experience in the healthcare industry including a decade of banking experience, she brings a powerful combination of transaction experience and strategic perspective from Investment Banking and operational leadership. Prior to VantAI, she served as CFO at Orum Therapeutics, where she led the company's strategic financing initiatives and orchestrated the sale of ORM-6151 to Bristol Myers Squibb for $100 million upfront with a total transaction value up to $180 million. She played a pivotal role in over $100M of financing and an IPO. Prior to joining Orum Therapeutics, she was Director of Healthcare Investment Banking at Citigroup, where she managed over 60 M&A transactions and financings for healthcare companies. She holds MBA - JD degrees from Northwestern University and is an attorney at law in New York State.

I am an experienced entrepreneur, venture capital investor and board member with a focus on digital health, women’s health, and tech-enabled companies. As a 2-time founder of successful start-ups and a “Trending 40 Power Woman in DC Tech,” I am passionate about accelerating innovation, managing change, and transforming organizations. I have extensive experience in building key partnerships; delivering top-of-the-funnel strategic insights; developing and launching products; leading and transforming organizations; and scaling start-up and early-stage companies.

Steve is a "startup midwife" who has spent the last decade helping inventors turn their discoveries into businesses, whether in a startup, a university, or even a refugee camp. He most recently led the George Shultz Innovation Fund at UChicago, where he nucleated and invested in University spinouts. Prior to UChicago he was an Associate for Ocean Tomo's Innovation Management practice, where he advised companies on how to acquire, develop, and commercialize technologies.

Rana Lonnen is a healthcare technology investor, entrepreneur, and molecular biologist. At Novartis, she leads strategic investments in technology companies, on a mission to transform the healthcare ecosystem and make positive impact on people’s lives. Previously, Rana was Head of Preclinical Development at a UK biotech, Auspherix; investment consultant to IP Group in London; Founder and CSO of a UK-based Biotech, Axendos therapeutics. Prior to this, she was a Wellcome Trust-backed principal investigator in drug discovery in the field of Infection, Immunity, and Inflammation, author and inventor on high impact peer-reviewed publications and patents; before this, Rana worked at Bristol-Myers Squibb, in sales and marketing. Rana holds a PhD in molecular biology and an MBA from Imperial College London. She personally cares about equitable healthcare, social justice, sustainability, and the future of antimicrobial resistance. In her downtime, Rana likes to make culinary experiments, be in nature, and read. Rana is a board observer at Aktana, Cota Healthcare, H1 Insights, Koneksa, Mekonos, NuvoAir, and Dopavision. She is based out of Basel, Switzerland.

Technology leader with the aim of improving the development and deployment of research software applications through the use of cutting edge technology and high quality development standards. Managing a large diverse organization to work together towards building both desktop and enterprise products that must integrate seamlessly across a wide swath of customer hardware and Cloud/HPC environments. Technical Specialties: C/C++, Python, Linux, QT, Cuda, CPU/GPU optimization, GUI development, cloud development and deployment. Design, Development and Deployment of highly efficient applications that must scale both locally on the machine and to hundreds of thousands of CPUs/GPUs. Full stack architecture design.

Industry experience includes 10 years to Vertex, 9 years at Bayer and 8 years at Schering-Plough as a medicinal chemistry lab head, project leader, and specialist in new drug discovery technologies. Freelance writer on science and pharmaceutical topics, with columns and articles appearing in Chemistry World, Contract Pharma, Pharmaceutical Executive, Genome Technology, and other publications. Author of the widely-read industry science and industry web site "In the Pipeline" (https://www.science.org/blogs/pipeline), quoted in Forbes, Fortune, the Wall Street Journal, etc. Specialties: Drug discovery research experience in oncology, metabolic disease, Alzheimer's, infectious disease and other therapeutic areas. Target experience in kinases, proteases, GPCRs, ion channels, nuclear receptors, and many additional categories.

Brian is an experienced life sciences investor who focuses on early to mid-stage companies. Prior to joining Norwest, Brian worked at Blackstone Life Sciences, where he helped lead over $1.5B of investments across biotech, medical devices, and diagnostics. He was a Board Observer or Alliance Committee Member at 5 companies, working closely with management teams on clinical trials, FDA approval process, and commercial strategy. Brian was previously an Engagement Manager at McKinsey & Company, where he advised companies across the healthcare industry. Brian has a medical degree from Stanford and MBA from Harvard. His research on prostate cancer, diabetic macular edema, and patient safety has been published in multiple peer-review journals.

A globally oriented technology executive leading research, biotech, and consumer products organizations through complex changes. I have built organizations for explosive growth, consolidated them in business downturns, and led merger/acquisition/divestiture programs. I have led teams in 20+ countries, led all aspects of IT including major business transformations and culture change across organizations. I am an adept strategic thinker with experience advising several early stage biotech firms, an advisory board member to a software startup, and board chair for large ($100M+) social services agency. I have set technology strategy, implemented global programs, fixed broken operating models, rebuilt teams, negotiated large scale partnerships, and always focused on business success.

Proven C-level leader with deep experience running global Fortune 500, start-up, and emerging pharmaceutical businesses, possessing the unique ability to blend, build, and strengthen performance from the ground up. Broad understanding of market strategy development within clinically diverse programs that achieve meaningful product differentiation. Significant accomplishments creating profitable business development and investment community partnerships within the C-suite. Strategy/Vision: Deep start-up, transaction and capital raising success through the establishment and guidance of Adiso, Adastra, and Churchill; creation and execution of clinical development and business strategy to lead the companies from formation; with the identification and advancement of multiple first-in-class drug product assets; negotiated and managed lucrative business development partnerships; business development and licensing with Baxalta, transaction to Cothera Bioscience and Sun Pharma FZE. Change Leadership: Adaptable and insightful leader instrumental in the cultural and team transformation of Onconova from a private 16-person medicinal chemistry company into a commercially prepared 67-employee Nasdaq listed company executing a successful Initial Public Offering (IPO). Commercial Innovation: Directly involved in numerous successful product development/co-development programs and commercial launches within oncology and specialty therapeutics. Demonstrated ability to employ unique approaches to value pricing and contracting within competitive markets. Execution/Implementation: Ability to visualize and articulate both long-term and near-term goals while promoting excellence through organization design, leverage of key functional areas, with clear decision making and process application. Global M&A: Marshalled Churchill Pharma through nine-month transaction process and successful sale of assets prior to product approval by FDA, while simultaneously preparing for a Churchill launch. While at Onconova, initiated and negotiated two separate license agreements for Japan/Korea and Europe

I am a highly motivated scientific leader in the biotech and pharmaceutical industry working at the interface of biology, chemistry, and computation. I have experience working across the large and small molecules spaces and across discovery and development.

Kimberly A. Nearing, M.S., is a Venture Partner at BVCF Management, leading U.S. investing activities including deal origination, execution, fundraising, investor relations, and portfolio management. Additionally, as Chief Business Officer for three biotech companies, she oversees business development, capital raising, and IPO campaigns, and serves as a board member for MaveriX Oncology and the RV Foundation in Washington, D.C. Kimberly has 20 years of international financial services experience in venture capital and investment banking, coupled with substantial life sciences and health tech domain experience in startups and public companies. She began her career at Amgen in BD and marketing, where she served on two product launch teams, and held an executive position at IBM Healthcare where she was elected to a 20-person team charged with developing IBM’s global healthcare strategy. Her career highlight is her global network, particularly in the U.S., Asia, and the Middle East, and cross-border deal-making experience. Her educational background includes an MSc with Honors from Harvard University, a BA in Economics with Distinction from the University of Michigan, and certificates in Healthcare AI/ML from Stanford University and Generative AI: Prompt Engineering from IBM.

Mika Newton is an accomplished and visionary leader serving as the CEO of xCures, a prominent healthcare technology company at the forefront of personalized treatment solutions and data-driven insights. With a deep passion for improving patient outcomes and transforming the healthcare landscape, Mika Newton has steered xCures to success through strategic direction, innovative thinking, and a relentless pursuit of excellence. Under Mika Newton's leadership, xCures has secured significant funding, developed its product portfolio, and forged strategic partnerships to revolutionize the delivery of personalized medicine. With a proven track record of driving growth and fostering collaboration, Mika Newton continues to position xCures as a trusted industry leader, harnessing the power of technology and data to empower healthcare providers, enhance patient experiences, and shape the future of healthcare.

Stephanie Oestreich is Managing Director of the Myeloma Investment Fund (MIF) and is the chair of the McCloy Alumni Association. She is also on the faculty of MIT, a member of SpringBoard Ventures, an advisor at grIP Venture Studio, to Biognosys (a Bruker company), Invitris, CART company CelineTx and to the drug development and investment company OrangeGrove Bio. Previously she was Chief Business Officer at Galecto, Vice President at cell therapy company Mnemo Therapeutics, a Venture Partner at RA Capital and Executive Vice President at Evotec where she built its North American investment arm and started an incubator with Samsara BioCapital. She also worked as International Business Leader at F. Roche Hoffmann-La Roche Ltd., and for Novartis in Business Development and in Commercial. Stephanie conducted the research for her Ph.D. in biochemistry in the lab of a Nobel Prize winner at Harvard Medical School and obtained an MPA from the Harvard Kennedy School.

Steve Pagliuca is the Chair, CEO and Founder of PagsGroup, an investment firm focused on high growth companies in tech, biotech, healthcare and the sports industry. He has played a leading role in investing in prominent tech, media, telecom and financial services businesses. PagsGroup was recently announced as a lead investor in Liquid AI, a pioneering liquid neural network technology company. In 2016, the Pagliuca Family Foundation helped create the Pagliuca Harvard Life Lab. With a focus on biotech and life sciences, the lab teams have raised $1.16 billion and incubated 59 companies. In addition, Pagliuca is the co-founder and executive chair of Arena BioWorks, a privately funded, fully independent biomedical institute. Pagliuca is a co-owner and managing partner of the Boston Celtics, president of the Shamrock Foundation and serves on the NBA Board of Governors. He is also a co-owner and co-chair of Atalanta Bergamasca Calcio, a professional football club based in Italy. Mr. Pagliuca received a B.A. from Duke University and an M.B.A. from the Harvard Business School.

I am an experienced physician-scientist-entrepreneur focused on starting, leading, and building companies that will positively impact healthcare across the spectrum of services, therapeutics, and devices. Chief Medical Officer, Contraline President, Clinical Care, Chief Medical & Scientific Officer, Vault Health Founder & CMO, Woven Health Associate Professor in Andrology / Male Infertility at University of Utah Entrepreneurial Endeavors: Chief Medical Officer, Contraline (2021) President, Clinical Care and Chief Medical & Scientific Officer, Vault Health (2019) Founder & CMO of Woven Health Inc. (2013), a digital health company developing the mobile platform for patient care team engagement, designed to enhance the productivity of healthcare professionals, improve the quality and safety of patient care, and reduce costs for healthcare institutions. Conception and development of "Vas Reverse" iPhone app (2012) to guide decision-making by patients seeking vasectomy reversal and urologic surgeons who perform these procedures. Clinical / Research Accomplishments: Successful clinical and basic science researcher?- Basic science interests focused on genetics of Peyronie's Disease and male infertility Over 140 peer-reviewed publications, 2 textbooks

Anthony Philippakis is committed to bridging the gap between data sciences and medicine. He originally trained as a cardiologist at Brigham and Women's Hospital. He is currently a General Partner at GV (formerly known as Google Ventures). Philippakis received his M.D. from Harvard Medical School and completed a Ph.D. in biophysics at Harvard. As an undergraduate, he studied mathematics at Yale University, and later completed the Part III (equivalent to M.Phil) in mathematics at Cambridge University.

As an early pioneer of microarray technology, Doug authored some of the first publications describing experimental and computational approaches for large scale transcriptional analyses. After completing his Ph.D. in George Church’s lab at Harvard, he joined the Novartis Institutes for Biomedical Research where his 14-year career spanned the entire drug discovery pipeline, including significant work in target ID/validation, high throughput screening, and preclinical safety. In 2017, Doug founded Plex Research to develop a novel form of AI based on search engine algorithms. Plex’s unique platform has helped dozens of biotech and pharma companies accelerate their drug discovery pipelines by providing interpretable and actionable analyses of massive chemical biology and omics data sets.

Matt is an accomplished product leader with over 15 years of data center and telecommunications industry experience based in Denver, CO. In his current role as VP of Interconnection Strategy, he is responsible for defining CoreSite’s product vision and roadmap while leading the product management and development team. Matt is passionate about utilizing market research and analysis to identify trends and opportunities to meet the evolution of our customers digital transformations

Woody Sherman is Founder and Chief Innovation Officer at Psivant Therapeutics and a thought leader in molecular simulations and computer-aided drug design, with over 90 peer-reviewed publications covering novel methods and applications. As Chief Computational Scientist at Roivant, Woody oversaw the computational strategy, implementation, and deployment of computational methods. He received his B.S. in Physical Chemistry from the University of California at Santa Barbara where he studied nonlinear optical properties of organic polymers using computational quantum mechanics methods. He completed his Ph.D. at MIT working in Professor Bruce Tidor’s lab where he examined the role of electrostatics in protein-ligand binding and implemented a novel method for optimizing ligand binding specificity across a panel of targets. While in graduate school he worked at Biogen where he developed novel methods to enhance antibody affinity via electrostatic charge optimization, resulting in a publication and patent. As Global Head of Applications Science at Schrödinger, led research, product development, methods development, and the deployment of Python-based tools. He also worked closely with Pharma partners on research projects and collaborations. Woody has published on a broad range of topics, including induced-fit docking, ensemble docking, molecular dynamics, free energy simulations, protein design, small molecule optimization, cheminformatics, hybrid ligand/structure-based methods, charge optimization, pharmacophore modeling, and more.

Claire is a partner at SpringTide and has spent her career focused at the intersection of healthcare, life sciences, and business. Prior to SpringTide, she was an investor at Meridian Street Capital, where she focused on seed-stage health tech, and Anterra Capital, where she focused on the intersection of biotech and agriculture while launching several animal health startups. Previously, she served as the Chief of Staff at Crestovo, a microbiome therapeutics startup acquired by Finch Therapeutics. She began her career at ClearView Healthcare Partners, a boutique life sciences consultancy, where she advised pharma and biotech clients on a variety of growth strategy topics. Claire holds bachelor’s degrees in biological engineering and management science from MIT. She is on the board of Leash Labs and serves as a board observer at IgniteData and Paterna Biosciences.

Rebecca Stevenson HSBC Rebecca (Becky) Stevenson is Head of Healthcare Investment Banking for the Americas at HSBC. Becky previously served as a Managing Director on the Biopharma Investment Banking team within the Healthcare Corporate & Investment Banking group at Wells Fargo where she advised, and executed on behalf of, biopharma companies’ long-term strategic financing, M&A, partnership and overall business development strategies.

Mariola Szenk is a venture investor at BlueYard Capital, backing founders creating deep tech solutions to transform biology and healthcare at the earliest stages. Prior to BlueYard, Mariola led industry partnerships with global pharma at Mayo Clinic backed life sciences AI company nference across both R&D and business strategy and served as an entrepreneur in residence at the venture creation studio Flagship Pioneering in their artificial intelligence division. Mariola conducted her PhD research in biophysical cellular modeling with Ken Dill and a postdoc in synthetic biology with Gabor Balazsi. She holds a Bachelor’s in Physics and Economics from the CUNY Macaulay Honors College.

Bharath is an inventor of multiple foundational life science technologies at the interface of nanotechnology, systems biology and ML/AI, being developed to extract 100x more information from systems biology (genotype and phenotype) than currently possible. He conceived of Sensor-integrated Proteome On Chip (SPOC) technology to bridge a large gap in the current proteomic tools space, to democratize high-throughput kinetic screening of protein bindings and interactions. SPOC is the first and only technology that enables production of 1000s of full-length folded proteins on 1.5 sq-cm biosensor chips, for simultaneous real time biosensing of protein bindings and interactions, to yield qualitative, quantitative and kinetic information in a single assay. Bharath has 20 years of experience at the interface of single molecule biophysics, solid-state-electronics and molecular biology and holds multiple patents in these areas. He is also the inventor of FENT solid-state nanopore technology for 1000x faster DNA sequencing at 1/10th the cost, being developed by iNanoBio Inc. Bharath’s vision is to develop complex scalable technologies, to achieve 90% disease preemption, which aims to detect and intervene in pre-disease phases, to cure before full disease onset.

Stef van Grieken is the co-founder and CEO of Cradle, a platform that enables scientists to engineer proteins with help from generative machine learning. Before founding Cradle he was Senior Product Manager and part of the leadership team at Google Research & Machine Intelligence where he managed a portfolio of infrastructure, developer and applied artificial intelligence projects. Before that, he was a co-lead of a Google X project and worked on Google Maps and Android. Stef received a master's degree in Industrial Engineering from the University of Groningen.

Dr. Jo Viney, Ph.D., is Cofounder, President and CEO of Seismic Therapeutic, the machine learning immunology company developing medicines for autoimmune disease. A seasoned biotech executive and entrepreneurial scientist, she has co-founded 3 biotech startup companies in MA - the first of which, Pandion Therapeutics, was acquired by Merck in 2021 for $1.85B. Prior to Pandion she held research leadership positions and contributed to the drug discovery pipelines at Biogen, Amgen, and Immunex. She is an experienced director on both private and public company boards. Jo is a big advocate for workplace inclusiveness and regularly volunteers her time with a number of organizations focused on increasing diversity.

Anna Marie Wagner’s career has spanned investing and operating roles in both hypergrowth and mature companies, focused on technology and the life sciences. She currently advises organizations across both the public and private sectors including DARPA and several private techbio innovators. Previously, Anna Marie was on the executive team at Ginkgo Bioworks (NYSE:DNA), where over the years she built and led numerous functions including finance, corporate development, and AI. Anna Marie led Ginkgo’s public offering in 2021, raising $1.6 billion in what still is the largest-ever go-public raise in biotech, and launched Ginkgo's AI efforts, including its marquee collaboration with Google. Previously, she was a technology investor at Bain Capital Private Equity where she focused on vertical software, marketplaces, and digital media businesses. Since 2023, she has also been serving as an Executive Fellow at Harvard Business School, where she co-teaches an elective course on failure (and loves the irony!). Anna Marie lives in Boston and her house is overrun with boys - in the form of a husband, two children, and two cats.

As co-founder of Blue and co-inventor of our core technology, Ajay directs scientific and experimental efforts at Blue. He has over 15 years of research experience in opioid medicinal chemistry and the neurobiology of pain. Ajay completed his doctoral studies in the lab of Dr. Philip Portoghese at the University of Minnesota. Ajay completed his postdoctoral training under renowned pain neurobiologist Clifford Woolf at Harvard Medical School. He has authored several papers published in high-impact, peer-reviewed journals in the CNS space, including several book chapters and invited reviews. He is also a recipient of the Bacaner Research Award from the Minnesota Medical Foundation.